SRX3225

SRX3225 is a novel small molecule triple inhibitor targeting histone deacetylase 6 (HDAC6), bromodomain-containing protein 4 (BRD4), and phosphatidylinositol 3-kinase (PI3K) family enzymes. It was designed using in silico methods leveraging cancer target structural data to achieve potent and selective inhibition of these three targets within a single molecule. SRX3225 exhibits picomolar potency against HDAC6 with high selectivity over other HDAC isoforms and selectively inhibits BRD4-BD1 over BRD4-BD2 as well as PI3K alpha and delta isoforms. This triple inhibitory action aims to create synergistic synthetic lethality in cancer cells by simultaneously blocking multiple key oncogenic signaling pathways with potentially less toxicity than combining three separate agents. The drug is being developed primarily for anticancer indications by the biotechnology company SignalRx Pharmaceuticals[1][2][4].

Other names

BRD4/HDAC6/PI3K Triple Inhibitor - SignalRxHDAC6/BRD4/PI3K Triple Inhibitor - SignalRxPI3K/BRD4/HDAC6 Triple Inhibitor - SignalRx